Campbell & Co Investment Adviser’s Neurocrine Biosciences NBIX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,338	Closed	-$899K	–	1297
2025 Q4	$899K	Sell	6,338 -10,132	-62%	-$1.47M	0.04%	605
2025 Q3	$2.31M	Buy	+16,470	New	+$2.23M	0.17%	147
2024 Q4	–	Sell	-15,836	Closed	-$1.82M	–	1258
2024 Q3	$1.82M	Buy	15,836 +11,055	+231%	+$1.52M	0.14%	217
2024 Q2	$658K	Buy	+4,781	New	+$656K	0.06%	539
2024 Q1	–	Sell	-2,239	Closed	-$295K	–	1285
2023 Q4	$295K	Buy	+2,239	New	+$258K	0.03%	925
2023 Q2	–	Sell	-9,963	Closed	-$1.01M	–	1043
2023 Q1	$1.01M	Buy	9,963 +5,869	+143%	+$611K	0.19%	158
2022 Q4	$489K	Sell	4,094 -1,884	-32%	-$221K	0.12%	328
2022 Q3	$635K	Buy	+5,978	New	+$607K	0.14%	243
2020 Q4	–	Sell	-8,029	Closed	-$772K	–	523
2020 Q3	$772K	Buy	+8,029	New	+$929K	0.58%	20
2020 Q1	–	Sell	-23,637	Closed	-$2.54M	–	340
2019 Q4	$2.54M	Buy	+23,637	New	+$2.47M	0.78%	2
2019 Q1	–	Sell	-3,115	Closed	-$246K	–	575
2018 Q4	$246K	Buy	+3,115	New	+$298K	0.24%	219

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Campbell & Co Investment Adviser's NBIX Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 6,338 shares — an estimated $899K sold.

Campbell & Co Investment Adviser first reported a position in NBIX in Q4 2018 and held it in 11 quarters. The position peaked at $2.54M in Q4 2019. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Campbell & Co Investment Adviser reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Campbell & Co Investment Adviser sold 6,338 Neurocrine Biosciences shares in Q1 2026, an estimated $899K.
Campbell & Co Investment Adviser first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 11 quarters.
Campbell & Co Investment Adviser's Neurocrine Biosciences position peaked at $2.54M in Q4 2019.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.